Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Saltzman

Showing results (71-80 of 284) with videos related to

Pageof 29
Sort By:
Brain Research|May 22, 1995
Distribution of nerve growth factor following direct delivery to brain interstitiumC E Krewson, M L Klarman, W M Saltzman
Clinical Orthopaedics and Related Research|September 30, 2010
Adult consequences of spina bifida: a cohort studyJames W Roach, Barbara F Short, Hanna M Saltzman
Molecular Medicine Today|April 1, 1995
Drug discovery and deliveryR K Jain, K D Janda, W M Saltzman
The Journal of Biological Chemistry|November 25, 1989
The 75,000-dalton interleukin-2 receptor transmits a signal for the activation of a tyrosine protein kinaseE M Saltzman, S M Luhowskyj, J E Casnellie
International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience|June 1, 1996
PC12 cell aggregation and neurite growth in gels of collagen, laminin and fibronectinS P Baldwin, C E Krewson, W M Saltzman
Child Psychiatry and Human Development|December 20, 2005
IQ and posttraumatic stress symptoms in children exposed to interpersonal violenceKasey M Saltzman, Carl F Weems, Victor G Carrion
Bio/Technology (Nature Publishing Company)|November 1, 1992
Controlled antibody delivery systemsJ K Sherwood, R B Dause, W M Saltzman
The Journal of Biological Chemistry|May 25, 1988
Activation of a tyrosine protein kinase is an early event in the stimulation of T lymphocytes by interleukin-2E M Saltzman, R R Thom, J E Casnellie
Journal of Biomedical Materials Research|July 6, 2000
Controlling human polymorphonuclear leukocytes motility using microfabrication technologyJ Tan, H Shen, K L Carter, et al.
Therapeutic Drug Monitoring|January 1, 1981
Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysisJ Chodos, E L Francke, M Saltzman, et al.
Pageof 29

Showing results (71-80 of 284) with videos related to

Sort By:
Pageof 29
Brain Research|May 22, 1995
Distribution of nerve growth factor following direct delivery to brain interstitiumC E Krewson, M L Klarman, W M Saltzman
Clinical Orthopaedics and Related Research|September 30, 2010
Adult consequences of spina bifida: a cohort studyJames W Roach, Barbara F Short, Hanna M Saltzman
Molecular Medicine Today|April 1, 1995
Drug discovery and deliveryR K Jain, K D Janda, W M Saltzman
The Journal of Biological Chemistry|November 25, 1989
The 75,000-dalton interleukin-2 receptor transmits a signal for the activation of a tyrosine protein kinaseE M Saltzman, S M Luhowskyj, J E Casnellie
International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience|June 1, 1996
PC12 cell aggregation and neurite growth in gels of collagen, laminin and fibronectinS P Baldwin, C E Krewson, W M Saltzman
Child Psychiatry and Human Development|December 20, 2005
IQ and posttraumatic stress symptoms in children exposed to interpersonal violenceKasey M Saltzman, Carl F Weems, Victor G Carrion
Bio/Technology (Nature Publishing Company)|November 1, 1992
Controlled antibody delivery systemsJ K Sherwood, R B Dause, W M Saltzman
The Journal of Biological Chemistry|May 25, 1988
Activation of a tyrosine protein kinase is an early event in the stimulation of T lymphocytes by interleukin-2E M Saltzman, R R Thom, J E Casnellie
Journal of Biomedical Materials Research|July 6, 2000
Controlling human polymorphonuclear leukocytes motility using microfabrication technologyJ Tan, H Shen, K L Carter, et al.
Therapeutic Drug Monitoring|January 1, 1981
Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysisJ Chodos, E L Francke, M Saltzman, et al.
Pageof 29